THE WOODLANDS, Texas, July 28, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company, announces the appointment of M. Zouhair Atassi, Ph.D. and Thomas Watts M.D. to the Scientific Advisory Board of the Company. Dr. Atassi is the current Robert A. Welch Chair of Chemistry and a Professor of Biochemistry and Molecular Biology at Baylor College of Medicine, while Dr. Watts is practicing medicine at the Kelsey-Seybold Clinic. They will provide the Company strategic point of views representing both the clinical and end-user perspectives of Power3's products.
Dr. Atassi, the current Robert A. Welch Chair of Chemistry and Professor of Biochemistry and Molecular Biology at Baylor College of Medicine, Houston, Texas, completed his Ph.D. in Chemistry, at the University of Birmingham, England. He most recently was the 2003 President of the Institute of Immunobiology and the current Editor-in-Chief for The Protein Journal, Protein Reviews and Critical Reviews in Immunology. The overall research interest of Dr. Atassi is in the areas of correlation of protein structure with function; protein-receptor interactions, protein-protein interactions, conformation of proteins and peptides, immune recognition of proteins by antibodies and by T cells; manipulation of the immune response, antigen presentation; design of synthetic peptide vaccines to neurotoxins and viral pathogens, peptide synthesis.
Dr. Watts has been board certified, from American Board of Family Practice since 1975 and is currently working as a resident physician at the Kelsey-Seybold Clinic, The Woodlands, Texas. He received his M.D. in 1972 from Baylor College of Medicine and practiced medicine at the Blue Earth Medical Center in Minnesota from 1975 to 1996. As a physician with more than 30 years of experience, Dr. Watts provides the Company with insights from the perspective of the end user of Power3's products.
Dr. Zouhair Atassi, commented, "I am very pleased to serve on the scientific advisory board. The programs and activities of Power3 Medical are very closely related to my own areas of expertise. The products resulting from these programs and activities should provide powerful tools for early detection and treatment of cancer, autoimmune and other diseases."
Dr. Thomas Watts, commented, "It is an honor to have this opportunity to come together with Power3 Medical and the other members of the scientific advisory board in the process of developing new diagnostic tests for diseases which currently have no early detection. I hope we as a team can bring about a true change in the ability to diagnose and treat patients, to ultimately enhance their quality of life."
About Power3 Medical Products, Inc.
Power3 Medical Products, www.Power3Medical.com, is a leading edge proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company is in a strong competitive position with over 250 identified biomarkers of human disease and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
In addition, all current shareholders, and interested parties should sign into our private Corporate Guest Book, www.CorporateGuestBook.com/?PWRM to receive timely updates and information on future developments.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.